Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DNAVision to offer Ipsogen's gene profiling tests for breast cancer:

This article was originally published in Clinica

Executive Summary

Marseille, France-based Ipsogen has secured a contract to supply DNAVision, a Belgium-based provider of pharmacogenomic testing services, with gene profiling tests for breast cancer. The agreement will see Ipsogen's tests being offered to institutions and patients in a CLIA/ISO17025 certified environment, "at the level of quality of quantitative PCR, the industry standard," said Ipsogen. The agreement comes shortly after the company gained a licence to Affymetrix' microarray technology, which is incorporated in Ipsogen's molecular diagnostic products.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts